Ethylestrenol
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Ethylestrenol
| |
| Systematic (IUPAC) name | |
| (8R,9S,10R,13S,14S,17S)-17-ethyl-13-methyl- 2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro- 1H-cyclopenta[a]phenanthren-17-ol | |
| Identifiers | |
| CAS number | |
| ATC code | A14 |
| PubChem | |
| Chemical data | |
| Formula | C20H32O |
| Mol. mass | 288.467 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Ethylestrenol | |
|
Articles | |
|---|---|
|
Most recent articles on Ethylestrenol Most cited articles on Ethylestrenol | |
|
Media | |
|
Powerpoint slides on Ethylestrenol | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Ethylestrenol at Clinical Trials.gov Trial results on Ethylestrenol Clinical Trials on Ethylestrenol at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Ethylestrenol NICE Guidance on Ethylestrenol
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Ethylestrenol Discussion groups on Ethylestrenol Patient Handouts on Ethylestrenol Directions to Hospitals Treating Ethylestrenol Risk calculators and risk factors for Ethylestrenol
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Ethylestrenol | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Ethylestrenol (Maxibolin®, Orabolin®) is an anabolic steroid with some progesterone-like activity, and little androgenic activity. It is a nandrolone derivative and lacks the 3-keto functional group.
Anabolic steroids (A14) (trademark names in brackets) | |
|---|---|
| Androstan (carbon 19 present) | Androstadienone • Boldenone undecylenate (Equipoise) • 4-Chlordehydromethyltestosterone (Turinabol) • Clostebol • Desoxymethyltestosterone (Madol) • DHEA • DHT • Drostanolone (Masteron) • Fluoxymesterone (Halotestin) • Furazabol (Miotolan) • Methandrostenolone (Dianabol) • Methenolone • Mesterolone (Proviron) • Methenolone enanthate (Primobolan) • Mestanolone • Norethandrolone • Oxandrolone (Anavar) • Oxymetholone (Anadrol) • Oxymetholone (Anadrol-50) • Quinbolone (Anabolicum Vister) • Stanozolol (Winstrol) • Testosterone |
| Estren (carbon 19 absent) | Ethylestrenol • Mibolerone (Cheque Drops) • Nandrolone (Deca Durabolin) • Norbolethone (Genabol) • Oxabolone cipionate • Tetrahydrogestrinone (The Clear) • Trenbolone (Fina) |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
